A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
연구 개요
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
- 스폰서
- 리드: 일라이 릴리
- 적응증
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- 중재
- Pirtobrutinib
- 목표 등록
- 787명
- 시작일
- 2025-05-20
- 완료(예정)
- 2032-12-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.